SMARCB1 and epithelioid sarcoma: To test the ability of pevonedistat to inhibit RMC and other SMARCB1‐deficient cell lines, we performed MTT assays on two RMC cell lines (RMC2C and RMC219) and in G‐401 (MRT) and VA‐ES‐BJ (epithelioid sarcoma) cell lines.